Exchange: NASDAQ Global Select Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
-3.52% $8.76
/ 15 nov 2022 @ 00:00
FUNDAMENTALS | |
---|---|
MarketCap: | 263.63 mill |
EPS: | -2.17 |
P/E: | -4.04 |
Earnings Date: | N/A |
SharesOutstanding: | 30.09 mill |
Avg Daily Volume: | 0.0650 mill |
RATING 2023-01-13 |
---|
B+ |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -4.04 | sector: PE 0 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -4.04 | industry: PE 0 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 8.42 - 9.10 ( +/- 3.85%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-18 | Morberg John D | Buy | 17 500 | Common Stock |
2024-01-18 | Morberg John D | Sell | 6 283 | Common Stock |
2024-01-18 | Morberg John D | Sell | 17 500 | Restricted Stock Unit |
2024-01-09 | Calloway Nathaniel | Buy | 5 906 | Common Stock |
2024-01-09 | Calloway Nathaniel | Sell | 5 906 | Restricted Stock Unit |
INSIDER POWER |
---|
81.50 |
Last 96 transactions |
Buy: 2 087 566 | Sell: 211 187 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $8.76 (-3.52% ) |
Volume | 0.0525 mill |
Avg. Vol. | 0.0650 mill |
% of Avg. Vol | 80.75 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Landec Corporation, together with its subsidiaries, designs, develops, manufactures, and sells differentiated health and wellness products for food and biomaterials markets in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. Landec Corporation was incorporated in 1986 and is headquartered in Santa Maria, California.